News Center

News Center

Shengshi Taikang Named Most Promising Innovative Pharmaceutical Company

Release date:

2022-08-16

 

Today, exciting news came from the 6th China Biopharmaceutical Innovation Collaboration Conference and the 2022 China Biopharmaceutical Industry Value List Awards Ceremony: Shengshi Taikang Selected as " Top 10 Most Promising Small-Molecule Innovative Pharmaceutical Companies "Ranking list." Over the past month, Shengshi Taikang has seen two of its innovative drug candidates under development receive dual approvals—one in China and one in the U.S.—marking the start of a new journey for its innovative medicines to go global.

 

This year's China Biopharmaceutical Innovation & Collaboration Conference focuses on cutting-edge technology insights, provides in-depth analysis of the latest industry policies, and connects key platforms spanning academia, research, industry, and finance. Notably, WanYi Medical, in collaboration with Huayi Research Institute, conducted a comprehensive evaluation of the industry, sectors, and individual companies across multiple dimensions—including strategic factors, product attributes, competitive dynamics, team capabilities, commercialization potential, and value propositions. After an extensive review process involving submissions, data verification, and systematic research, the "2022 China Biopharmaceutical Industry Value Ranking" was finalized and officially unveiled at the conference's plenary session.

 

Founded in 2010 in Suzhou Industrial Park, Shengshi Taikang boasts a core team with decades of international experience spanning the entire lifecycle of pharmaceutical products. The company is dedicated to the research, development, and industrialization of innovative small-molecule drugs aimed at groundbreaking therapies. Leveraging an integrated drug R&D technology platform and a diversified business perspective, Shengshi Taikang has built a robust pipeline of cutting-edge drug candidates, targeting key therapeutic areas such as diabetes management, cancer treatment, and rare diseases.

 

Recently, all three of these therapeutic areas have been making steady gains. In the diabetes field, the novel drug DPP-4 inhibitor saxagliptin phosphate has already entered Phase III clinical trial nearing completion , poised to fill the gap in domestically produced, original oral antidiabetic drugs; among the cancer drugs currently in development, three have already entered clinical trials, and the FGFR/VEGFR dual-target inhibitor CGT-6321 has already been Phase I clinical trial initiated in advanced solid tumors , this drug is poised to become a potential first-in-class medication; the CXCR4 antagonist CGT-1881 is used for mobilizing hematopoietic stem cells, Oral administration is more convenient. ; The next-generation ALK/RET inhibitor CGT-9475 holds promise Addressing key clinical challenges in lung cancer treatment, such as drug resistance and brain metastasis. Both of the first two projects have received clinical approval from the U.S. FDA, marking a solid step forward for the company’s innovative drugs in entering international markets. Additionally, China’s first generic version of teriflunomide tablets—a treatment for the rare disease multiple sclerosis—is set to officially launch and become available on the market soon, offering domestic patients high-quality medication at more affordable prices.

Prev：

Media Spotlight | Dr. Wang Tong: Embarking on the "Stellar Voyage" of Drug Discovery, Starting from a Fragment-Molecule Library

Next：

Biopharmaceutical professionals now have their own platform for professional title evaluations.

中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地